Be sure to catch up on the latest happenings in our spring newsletter here! Nancy Farrugia Related postsIntellia Therapeutics Announces First Patient Dosed in the HAELO Phase 3 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary AngioedemaJanuary 22, 2025Intellia and Regeneron Announce Initial Data from the Cardiomyopathy Arm of Ongoing Phase 1 Study of NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) AmyloidosisSeptember 16, 20222024 Fall NewsletterSeptember 25, 2024 Previous post2026 Winter Newsletter